Home › Trial NCT05461794
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Trial IDNCT05461794
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorBeiGene
- Enrollment96
- Start date2022-10-03
- ConditionsEsophageal Squamous Cell Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.